As Covarrublias et al. concluded in their article, when PARPs, CD38, SARM1, and some other NAD+-depleting substances were inhibited, NAD+ levels in AD were significantly increased, and AD brain dysfunction and cognitive impairment were improved [11]. This evidence concerns the gene CD38 and Alzheimer disease.